References

  1. https://sunpharma.com/wp-content/uploads/2024/07/SPIL-Annual-Report-2023-24.pdf
  2. https://sunpharma.com/wp-content/uploads/2024/01/SPIL-IR-Presentation-Jan-2024-INR-1.pdf
  3. https://www.emergenresearch.com/blog/top-10-globally-leading-and-prominent-dermatology-industry-leaders-revealed
  4. https://www.businesswire.com/news/home/20240807575035/en/Crescita-Reports-Second-Quarter-2024-Results
  5. https://www.reuters.com/plus/acumen/global-health/almirall-innovation-skin-disease
  6. https://www.almirall.com/newsroom/news/almirall-s-h1-2024-results
  7. https://www.almirall.com/our-expertise/r-d-at-almirall/pipeline
  8. https://www.ryonpharma.com/top-10-derma-companies-in-world
  9. https://companiesmarketcap.com/gbp/roivant-sciences/revenue/\https://companiesmarketcap.com/inr/roivant
  10. sciences/revenue/#:~:text=Revenue%20in%202024%20(TTM)%3A,were%20of%20%E2%82%B93.56%20Billion
  11. https://investor.roivant.com/news-releases/news-release-details/roivant-reports-financial-results-fourth-quarter-and-fiscal-0#:~:text=Dermavant%3A%20For%20the%20fourth%20quarter,15%2C300%20unique%20prescribers%20for%20psoriasis
  12. https://dermavant.com/pipeline/
  13. https://alphynbiologics.com/pipeline/
  14. https://pitchbook.com/profiles/company/158722-48#stock
  15. https://www.dermbiont.com/in-the-news/2023/10/24/dermbiont-announces-first-close-of-352-million-in-a-series-b-financing-to-advance-first-in-class-targeted-topical-dermatological-therapeutics
  16. https://www.pharmaceutical-technology.com/news/dermbiont-raises-35-2m-in-series-b-for-dermatological-therapies/
  17. https://www.galderma.com/news/galderma-announces-record-2023-net-sales-over-4-b-usd-and-significant-core-ebitda-margin
  18. https://www.galderma.com/news/galderma-delivers-record-net-sales-3259-b-usd-first-nine-months-2024-demonstrates-0#:~:text=In%20the%20first%20nine%20months%20of%202024%2C%20Galderma%20achieved%20record,across%20product%20categories%20and%20geographies.
  19. https://www.galderma.com/sites/default/files/2024-03/Galderma_AR_2023_Part1_Online_240320.pdf
  20. https://www.galderma.com/us/bringing-innovation-life
  21. https://via.ritzau.dk/pressemeddelelse/14111384/leo-pharma-continues-to-deliver-double-digit-revenue-growth-backed-by-strong-dermatology-sales?publisherId=12353927&lang=da
  22. https://www.leo-pharma.com/media-center/news/2024-pharma-announces-annual-results-2023
  23. https://www.leo-pharma.com/our-science/view-our-pipeline
  24. https://companiesmarketcap.com/inr/johnson-and-johnson/revenue/
  25. https://www.globenewswire.com/news-release/2024/10/23/2967618/0/en/Stifel-Reports-Third-Quarter-2024-Results.html#:~:text=Through%20the%20first%20three%20quarters,stabilization%20of%20net%20interest%20income.
  26. https://www.amgenpipeline.com/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/PDF/amgen-pipeline-chart.pdf
  27. https://www.stifel.com/docs/pdf/investorrelations/annualreports/annual2023.pdf
  28. https://ca.gsk.com/en-ca/products/stiefel-dermatology/
  29. https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-stiefel-to-create-new-world-leading-specialist-dermatology-business/#:~:text=around%20the%20world.%E2%80%9D-,New%20world%2Dleading%20specialist%20dermatology%20business,lead%20the%20new%20business%20thereafter.
  30. https://ca.gsk.com/en-ca/products/stiefel-dermatology/
  31. https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-stiefel-to-create-new-world-leading-specialist-dermatology-business/#:~:text=around%20the%20world.%E2%80%9D-,New%20world%2Dleading%20specialist%20dermatology%20business,lead%20the%20new%20business%20thereafter.
  32. https://ca.gsk.com/en-ca/products/stiefel-dermatology/
  33. https://my.clevelandclinic.org/health/diseases/21573-skin-diseases
  34. https://www.niams.nih.gov/health-topics/skin-diseases
  35. https://www.nccih.nih.gov/health/skin-conditions-at-a-glance#:~:text=Common%20skin%20conditions%20include%20acne,called%20eczema)%2C%20and%20psoriasis.
  36. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1145513/full
  37. https://knowledge-action-portal.com/en/news_and_events/news/9253
  38. https://www.aad.org/media/stats-numbers
  39. https://onlinelibrary.wiley.com/doi/10.1111/myc.13787?af=R
  40. https://www.who.int/news/item/31-03-2023-who-first-global-meeting-on-skin-ntds-calls-for-greater-efforts-to-address-their-burden
  41. https://www.trillianthealth.com/market-research/studies/skin-disease-prevalence-evolving-dermatology-treatments
  42. https://globalskin.org/doclink/skin-diseases-as-a-global-public-health-priority/eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiJza2luLWRpc2Vhc2VzLWFzLWEtZ2xvYmFsLXB1YmxpYy1oZWFsdGgtcHJpb3JpdHkiLCJpYXQiOjE3MTY0OTc4NzksImV4cCI6MTcxNjU4NDI3OX0.1VKfoy3Nd_ZJMr-JI0uCV1cSSI41uCjrDjSrbdMmNk0
  43. https://www.wcrf.org/cancer-trends/skin-cancer-statistics/
  44. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1145513/full#F1
  45. https://www.niams.nih.gov/health-topics/skin-diseases
  46. https://www.statista.com/outlook/hmo/otc-pharmaceuticals/skin-treatment/worldwide#revenue
  47. https://www.ncbi.nlm.nih.gov/books/NBK11733/
  48. https://www.magazine.medicaltourism.com/article/best-countries-in-the-world-for-advanced-dermatology-treatments#:~:text=South%20Korea:%20A%20Hub%20of,most%20current%20and%20effective%20care.
  49. https://www.ncbi.nlm.nih.gov/books/NBK92761/#:~:text=Herbal%20remedies%2C%20including%20those%20for,also%20included%20in%20this%20discussion.
  50. https://www.trillianthealth.com/market-research/studies/skin-disease-prevalence-evolving-dermatology-treatments#:~:text=The%20market%20for%20topical%20skin,pharmaceutical%20advancements%20and%20growing%20consumer
  51. https://finance.yahoo.com/news/topical-drug-delivery-market-size-155400620.html
  52. https://www.biospace.com/topical-drug-delivery-market-size-to-reach-usd-238-38-billion-by-2033
  53. https://www.sciencedirect.com/science/article/pii/S0928098724002264#:~:text=Delivery%20of%20APIs%20via%20the,)%2C%20(Figure%201).
  54. https://www.globenewswire.com/news-release/2024/10/03/2957841/0/en/Topical-Drug-Delivery-Market-is-expected-to-generate-a-revenue-of-USD-177-97-Billion-by-2031-Globally-at-6-3-CAGR-Verified-Market-Research.html
  55. https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2023-financial
  56. https://news.abbvie.com/2024-02-02-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-Results
  57. https://www.statista.com/statistics/417030/revenue-of-abbvie/#:~:text=AbbVie's%20revenue%202010%2D2023&text=This%20statistic%20illustrates%20the%20revenue,the%20acquisition%20of%20Allergan%20plc.
  58. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-skin-disease-drug-found-be-more-effective-than-regenerons-dupixent-study-2024-04-25/#:~:text=Atopic%20dermatitis%2C%20a%20specific%20form,global%20sales%20in%20fiscal%202023.
  59. https://www.abbvie.com/science/pipeline.html
  60. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2023/
  61. https://www.pharmaceutical-technology.com/news/pfizer-revenue-2023/?cf-view&cf-closed
  62. https://www.cnbc.com/2024/10/29/pfizer-pfe-earnings-q3-2024.html
  63. https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_29OCT2024.pdf?VersionId=E70MbubUKVzMZ8UF6fmYfS3KDJLP3pmH
  64. https://www.dermatologytimes.com/view/dermatology-drug-pipeline-2023
  65. https://www.reuters.com/plus/acumen/global-health/almirall-innovation-skin-disease
  66. https://alphynbiologics.com/platform/
  67. https://dermaliq.com/#pipeline
  68. https://www.businesswire.com/news/home/20240807575035/en/Crescita-Reports-Second-Quarter-2024-Results
  69. https://www.crescitatherapeutics.com/pipeline
  70. https://carocellbio.com/therapeutic-pipeline/
  71. https://www.startus-insights.com/innovators-guide/5-top-startups-developing-dermatological-drugs/
  72. https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-acquires-confluence-life-sciences-inc#:~:text=About%20Aclaris%20Therapeutics%2C%20Inc.,at%20www.aclaristx.com.
  73. https://www.aclaristx.com/pipeline/
  74. https://www.aclaristx.com/#:~:text=Home%20%7C%20Aclaris%20Therapeutics%20Inc.,View%20our%20pipeline%20%C2%B
  75. https://www.webmd.com/skin-problems-and-treatments/eczema/atopic-dermatitis-eczema
  76. https://www.mayoclinic.org/diseases-conditions/hair-loss/symptoms-causes/syc-20372926
  77. https://www.dermbiont.com/in-the-news/2023/5/30/dermbiont-announces-positive-data-from-a-phase-2-trial-treating-solar-lentigos-and-normalizing-pigmentation-of-the-skin-with-08-sm-030-topical-gel
  78. https://www.dermbiont.com/in-the-news/2021/12/21/dermbiont-raises-28-million-and-acquires-chromaderm-to-expand-targeted-topical-therapeutics-in-development
  79. https://www.mayoclinic.org/diseases-conditions/psoriasis/symptoms-causes/syc-20355840
  80. https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243
  81. https://www.sanofi.com/en/media-room/press-releases/2024/2024-01-16-12-00-00-2809681
  82. https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-26-15-40-00-2038798
  83. https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-study-results-immunology-kymab/654027/
  84. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-gets-us-fda-nod-for-its-specialty-drug-against-baldness/articleshow/112034458.cms?from=mdr
  85. https://www.business-standard.com/companies/news/sun-pharma-s-leqselvi-launch-in-us-faces-legal-roadblock-analysts-cautious-124110401105_1.html
  86. https://www.delveinsight.com/blog/promising-alopecia-areata-treatment-options
  87. https://www.moneycontrol.com/news/business/earnings/sun-pharmas-hair-loss-drug-leqselvis-launch-remains-in-limbo-12853092.html
  88. https://investor.incyte.com/news-releases/news-release-details/incyte-acquires-rights-lilly-develop-and-commercialize
  89. https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2023-fourth-quarter-and-year-end-financial
  90. https://www.amgen.com/newsroom/press-releases/2019/11/amgen-completes-acquisition-of-otezla-apremilast#:~:text=THOUSAND%20OAKS%2C%20Calif.%20%2C%20Nov,ulcers%20associated%20with%20Beh%C3%A7et's%20Disease.
  91. https://www.amgen.com/newsroom/press-releases/2019/08/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits
  92. https://www.webmd.com/skin-problems-and-treatments/acne/features/severe-acne
  93. https://www.aad.org/public/diseases/acne/derm-treat/adult-acne-natalie-story#:~:text=Natalie%20recalls%2C%20%E2%80%9CDr.,was%20huge%2C%E2%80%9D%20she%20added.
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC6994586/#:~:text=Nicola%20completed%20treatment%20with%20isotretinoin,she%20had%20started%20the%20drug.&text=Indeed%2C%20Nicola's%20efficacious%20clinical%20results,esteem%20and%20outlook%20toward%20life.
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC8903225/#:~:text=8%2C33%20The%20United%20States,Figure%201%2C%20Table%201).
  96. https://investor.mylan.com/news-releases/news-release-details/mylan-laboratories-inc-announces-first-anda-approval#:~:text=Mylan%20Laboratories%20Inc.,to%20Market%20Amnesteem%20%7C%20Mylan%20N.V.
  97. https://www.ncbi.nlm.nih.gov/books/NBK525949/#:~:text=Isotretinoin%20is%20an%20oral%20prescription,coordination%20for%20patients%20receiving%20isotretinoin.
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC7017847/
  99. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-first-patient-dosed-phase-2-atopic/
  100. https://www.clinicaltrialsarena.com/news/kymera-hidradenitis-suppurativa-trial/#:~:text=Kymera%20Therapeutics%20Inc&text=Under%20a%20partnership%20deal%20with,additional%20milestone%20payment%20from%20Sanofi.
  101. https://www.drugs.com/condition/hidradenitis-suppurativa.html#:~:text=The%20medications%20listed%20below%20are,Brands%20and%20Generics
  102. https://adisinsight.springer.com/

Pharma Insight Reports

https://adisinsight.springer.com/pharma-insight-reports